EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Inhaled Sedation in Acute Respiratory Distress Syndrome

Matthieu Jabaudon, Jean-Pierre Quenot, Julio Badie, Jules Audard, Samir Jaber, Benjamin Rieu, Caroline Varillon, Antoine Monsel, François Thouy, Julien Lorber, Joël Cousson, Stéphanie Bulyez und 32 weitere

JAMA · 13.05.2025 · 333 (18) · 1608

DOI: 10.1001/jama.2025.3169 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 13.05.2025. Verfasst von Matthieu Jabaudon und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Perioperative Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Anesthetics, Inhalation, Anesthetics, Intravenous, Hypnotics and Sedatives, Propofol. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Whether the use of inhaled or intravenous sedation affects outcomes differentially in mechanically ventilated adults with acute respiratory distress syndrome (ARDS) is unknown.

Objective

To determine the efficacy and safety of inhaled sevoflurane compared with intravenous propofol for sedation in patients with ARDS. Design, Setting, and Participants Phase 3 randomized, open-label, assessor-blinded clinical trial conducted from May 2020 to October 2023 with 90-day follow-up. Adults with early moderate to severe ARDS (defined by a ratio of Pao 2 to the fraction of inspired oxygen of <150 mm Hg with a positive end-expiratory pressure of ≥8 cm H 2 O) were enrolled in 37 French intensive care units.

Interventions

Patients were randomized to a strategy of inhaled sedation with sevoflurane (intervention group) or to a strategy of intravenous sedation with propofol (control group) for up to 7 days. Main Outcomes and Measures The primary end point was the number of ventilator-free days at 28 days; the key secondary end point was 90-day survival.

Results

Of 687 patients enrolled (mean [SD] age, 65 [12] years; 30% female), 346 were randomized to sevoflurane and 341 to propofol. The median total duration of sedation was 7 days (IQR, 4 to 7) in both groups. The number of ventilator-free days through day 28 was 0.0 days (IQR, 0.0 to 11.9) in the sevoflurane group and 0.0 days (IQR, 0.0 to 18.7) in the propofol group (median difference, −2.1 [95% CI, −3.6 to −0.7]; standardized hazard ratio, 0.76 [95% CI, 0.50 to 0.97]). The 90-day survival rates were 47.1% and 55.7% in the sevoflurane and propofol groups, respectively (hazard ratio, 1.31 [95% CI, 1.05 to 1.62]). Among 4 secondary outcomes, sevoflurane was associated with higher 7-day mortality (19.4% vs 13.5%, respectively; relative risk, 1.44 [95% CI, 1.02 to 2.03]) and fewer intensive care unit–free days through day 28 (median, 0.0 [IQR, 0.0 to 6.0] vs 0.0 [IQR, 0.0 to 15.0]; median difference, –2.5 [95% CI, –3.7 to –1.4]) compared with propofol. Conclusions and Relevance Among patients with moderate to severe ARDS, inhaled sedation with sevoflurane resulted in fewer ventilator-free days at day 28 and lower 90-day survival than sedation with propofol. Trial Registration ClinicalTrials.gov Identifier: NCT04235608

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anesthetics, InhalationAnesthetics, IntravenousHypnotics and SedativesPropofolRespiratory Distress SyndromeSevofluraneAgedFemaleHumansMaleMiddle AgedAdministration, InhalationRespiration, ArtificialIntensive Care UnitsSeverity of Illness IndexHospital MortalityAdministration, IntravenousTreatment Outcome

Substanzen

Anesthetics, InhalationAnesthetics, IntravenousHypnotics and SedativesPropofolSevoflurane

Autor:innen und Institutionen

  • Department of Perioperative Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • iGReD, CNRS, INSERM, Université Clermont Auvergne, Clermont-Ferrand, France.
  • The Lipness Team, INSERM Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and LabEx LipSTIC, INSERM Centre d'Investigation Clinique 1432, Clinical Epidemiology, Université de Bourgogne, and Médecine Intensive Réa…
  • Réanimation Polyvalente, Hôpital Nord Franche-Comté, Trévenans, France.
  • Centre Hospitalier Universitaire (CHU) Montpellier, Département Anesthésie Réanimation B, Hôpital Saint Eloi and PhyMedExp, INSERM U1046, Université de Montpellier, Montpellier, France.
  • Department of Medical Intensive Care, Dunkerque Hospital, 59240 Dunkerque, France.

Zitieren

APA

Jabaudon, M., Quenot, J. P., Badie, J., Audard, J., Jaber, S., Rieu, B., Varillon, C., Monsel, A., Thouy, F., Lorber, J., Cousson, J., Bulyez, S., Bourenne, J., Sboui, G., Lhommet, C., Lemiale, V., Bouhemad, B., Brault, C., Lasocki, S., …, & SESAR Trial Investigators (2025). Inhaled Sedation in Acute Respiratory Distress Syndrome. JAMA, 333(18), 1608. https://doi.org/10.1001/jama.2025.3169

Vancouver

Jabaudon M, Quenot JP, Badie J, Audard J, Jaber S, Rieu B, et al. Inhaled Sedation in Acute Respiratory Distress Syndrome. JAMA. 2025;333(18):1608. doi:10.1001/jama.2025.3169

BibTeX
@article{Jabaudon2025,
  author = {Jabaudon, Matthieu and Quenot, Jean-Pierre and Badie, Julio and Audard, Jules and Jaber, Samir and Rieu, Benjamin and Varillon, Caroline and Monsel, Antoine and Thouy, François and Lorber, Julien and Cousson, Joël and Bulyez, Stéphanie and Bourenne, Jérémy and Sboui, Ghada and Lhommet, Claire and Lemiale, Virginie and Bouhemad, Belaïd and Brault, Clément and Lasocki, Sigismond and Legay, François and Lebouvier, Thomas and Durand, Arthur and Pottecher, Julien and Conia, Alexandre and Brégeaud, Delphine and Velly, Lionel and Thille, Arnaud W and Lambiotte, Fabien and L'Her, Erwan and Monchi, Mehran and Roquilly, Antoine and Berrouba, Aziz and Verdonk, Franck and Chabanne, Russell and Godet, Thomas and Garnier, Marc and Blondonnet, Raiko and Vernhes, Jérémy and Sapin, Vincent and Borao, Lucile and Futier, Emmanuel and Pereira, Bruno and Constantin, Jean-Michel and SESAR Trial Investigators, SESAR Trial Investigators},
  title = {Inhaled Sedation in Acute Respiratory Distress Syndrome},
  journal = {JAMA},
  year = {2025},
  volume = {333},
  number = {18},
  pages = {1608},
  doi = {10.1001/jama.2025.3169}
}
Kostenlos starten →